# Efficacy and Safety of Candesartan Associated With Chlorthalidone Versus Losartan Associated With Hydrochlorothiazide (Hyzaar®) in Essential Hypertension Control

> **NCT02521246** · PHASE3 · WITHDRAWN · sponsor: **EMS**

## Conditions studied

- Essential Arterial Hypertension

## Interventions

- **DRUG:** Candesartan + Chlorthalidone
- **DRUG:** Candesartan + Chlorthalidone
- **DRUG:** Losartan+hydrochlorothiazide

## Key facts

- **NCT ID:** NCT02521246
- **Lead sponsor:** EMS
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-11
- **Primary completion:** 2017-05
- **Final completion:** 2017-08
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2017-01-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02521246

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02521246, "Efficacy and Safety of Candesartan Associated With Chlorthalidone Versus Losartan Associated With Hydrochlorothiazide (Hyzaar®) in Essential Hypertension Control". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02521246. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*